Advanced Materials · 2018 · 50 citations · 19 references
PharmacyPharmaceuticsPharmacologyBiomaterialsBone MetabolismDrug DeliveryControlled Release MechanismsDrug Delivery BiomaterialsDrug EncapsulationNanocarriers For TherapeuticsNanoparticle Delivery SystemsOsteoporosis PharmacotherapyMicelle-based Responsive ReleaseMicroparticle Delivery SystemsMicroparticle FormulationsMicroparticlesNitric OxidePhase-change MaterialsSubcutaneous Drug AdministrationTherapeutic Efficacy Assessment
Treatment with exogenous nitric oxide (NO) donors is regarded as being effective against osteoporosis. However, NO has a short half-life, limiting its clinical usefulness. To overcome this limitation, an injectable microparticle (MP) system is developed that consists of phase-change materials capric acid (CA) and octadecane, and encapsulates a NO donor. The therapeutic efficacy of the MPs is evaluated in ovariectomized (OVX) rats with osteoporosis. Upon subcutaneous administration, the MPs undergo a phase transition, leaching out the NO donor and generating NO bubbles that are instantly covered by a layer of tightly packed CA surfactant molecules, forming micellar depots. The in situ self-assembling micellar depots can actively protect the NO bubbles, prolonging their half-life, while the entrapped NO may passively diffuse through the micellar depots over time, performing a long-lasting therapeutic function, reversing the OVX-induced osteoporosis. It is possible to use the concept of in situ self-assembling micellar depots developed herein to expand the therapeutic effect of NO in its diverse range of clinical applications.
19
Half-life of nitric oxide in aqueous solutions with and without haemoglobin
T. S. Hakim, Kunio Sugimori, Enrico M. Camporesi et al. · Physiological Measurement · 1996 · 165 citations
Estrogen receptor ß is involved in the anorectic action of estrogen
Y-Q Liang, Masahiro Akishita, S Kim et al. · International Journal of Obesity · 2002 · 147 citations